Vitekta

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Elvitegravir 150mg;  ;  ;  ;  

Disponible depuis:

Gilead Sciences (NZ)

DCI (Dénomination commune internationale):

Elvitegravir 150 mg

Dosage:

150 mg

forme pharmaceutique:

Film coated tablet

Composition:

Active: Elvitegravir 150mg         Excipient: Croscarmellose sodium Hyprolose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Opadry green 85F91203 Sodium laurilsulfate

Type d'ordonnance:

Prescription

Fabriqué par:

Catalent Micron Technologies Inc

indications thérapeutiques:

Indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults and adolescents when co-administered with a ritonavir-boosted protease inhibitor and other antiretroviral therapy.

Descriptif du produit:

Package - Contents - Shelf Life: Bottle, plastic, HDPE with child resistant PE cap - 30 tablets - 24 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2013-11-04